Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
about
Garlic intake is an independent predictor of endothelial function in patients with ischemic strokeHyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-β-D-glucoside.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study.Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factorsMetformin high dosage and bleeding episode: A clinical case study.Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women.Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents.Pleiotropic effects of acarbose on atherosclerosis development in rabbits are mediated via upregulating AMPK signals.Resveratrol in cardiovascular disease: what is known from current research?Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.Blood glucose-lowering effect of Tectona grandis flowers in type 2 diabetic rats: a study on identification of active constituents and mechanisms for antidiabetic action.Effect of Metformin, Acarbose and Their Combination on the Serum Visfatin Level in Nicotinamide/Streptozocin-Induced Type 2 Diabetic Rats.The lysosome among targets of metformin: new anti-inflammatory uses for an old drug?PPARγ activation inhibits cerebral arteriogenesis in the hypoperfused rat brain.Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo.Antidiabetic potential of methanolic and flavonoid-rich leaf extracts of Synsepalum dulcificum in type 2 diabetic rats.Platelets and diabetes: a complex association.Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events.Achieving triple treatment goals in multi-ethnic Asian patients with type 2 diabetes mellitus in primary careSelenocysteine mimics the effect of dietary restriction on lifespan via SKN‑1 and retards age‑associated pathophysiological changes in Caenorhabditis elegans
P2860
Q26254041-AA8EB6FB-E5FF-4470-874A-1F987B85CEDCQ33892587-A905F9D6-60EE-4620-9CEF-64A4D0616232Q33993320-C42ED173-CA48-4E29-AB1A-7D8F4CE7359BQ34100788-31D401A5-DF34-43FD-9CB0-9208A56805DCQ34133889-E130E92E-8DC5-4921-9BCB-039F0C67C598Q35073367-8211FE61-F706-4684-98A9-739654CE1AABQ36782688-E05B2316-3EDA-4814-BDB3-EB7705E995E6Q37210143-30509FAC-D00D-4512-B45A-E79A8DE1A372Q37472745-66C407C6-7ECC-496C-95B6-9C82BCD825C9Q37480157-EA5885CB-8825-4D52-BD0D-1F96CE82A634Q37891880-1E0762D3-B0F5-45C7-A7EB-4C153B67D9D5Q38038097-6C592081-3EA7-4B23-A57F-865C608909F9Q39037087-B69CF927-DD35-4E94-81CC-B0C410B61FFFQ39719551-2AA8696C-B490-4321-B991-93371B8DEF2FQ39882878-43DFA0B3-95E2-406D-ADBD-0A82630CE2CBQ40143324-00863B73-6112-43FA-A711-E24766C19DB9Q41841136-119B5246-DC1D-4FEE-AF30-2C98049F0D5DQ46966397-3037DA78-4227-4A67-8A08-F6F084EF59C9Q53130761-C03C74FA-83C5-4DAB-AA1B-F1E2EA8FEE01Q55049744-BBB67ABB-57C9-4D19-BC28-FD55CF00B4B2Q57300916-62382DB0-3407-4522-BB99-96D877B14D14Q58568596-86977841-3941-4876-9448-9276AFBC176E
P2860
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@en
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@nl
type
label
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@en
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@nl
prefLabel
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@en
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@nl
P1476
Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?
@en
P2093
P304
P356
10.2174/138161209789057995
P577
2009-01-01T00:00:00Z